Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies

In the last few years, there have been significant advances in migraine management and prevention. Lasmiditan, ubrogepant, rimegepant and monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) are new drugs that were launched on the US pharmaceutical market; some of them also...

Descripción completa

Detalles Bibliográficos
Autor principal: Szkutnik-Fiedler, Danuta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761673/
https://www.ncbi.nlm.nih.gov/pubmed/33287305
http://dx.doi.org/10.3390/pharmaceutics12121180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761673/
https://www.ncbi.nlm.nih.gov/pubmed/33287305
http://dx.doi.org/10.3390/pharmaceutics12121180

Ejemplares similares